News >

SL-401 Emerging as First Targeted Therapy for Rare Blood Cancer

Angelica Welch
Published: Thursday, Aug 16, 2018

Naveen Pemmaraju, MD

Naveen Pemmaraju, MD

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy for which there are few treatment options outside of cytotoxic chemotherapy. A new investigational agent, SL-401 (tagraxofusp, Elzonris), may provide an effective targeted therapy for patients with BPDCN, according to Naveen Pemmaraju, MD.

 
Findings from a pivotal phase II trial presented at the 2018 European Hematology Association Congress showed that SL-401 was active in this patient population and had a manageable safety profile. Overall response rate (ORR) was 90% for patients treated with SL-401 as frontline therapy, reported Pemmaraju.

In August 2018, the FDA granted a priority review designation to a biologics license application (BLA) for SL-401 as a treatment for patients with BPDCN. The agency is scheduled to decide on the BLA by February 21, 2019.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 3rd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesNov 29, 20192.0
Advances in™ ALL: The Role of T-Cell Engaging Immunotherapy in Treating Relapsed DiseaseNov 30, 20191.0
Publication Bottom Border
Border Publication
x